trazodone

• Antidepressant efficacy (response, 50% reduction in Hamilton depression rating scale)

  no effect

  All the studies found no significant difference in the efficacy of trazodone and imipramine

  PMID:1532532 · one of two readings recorded this

• antidepressant response, 50% reduction on the Hamilton depression rating scale, trazodone versus imipramine

  no effect

  Not recorded as a finding: the comparison was against another active treatment

  All the studies found no significant difference in the efficacy of trazodone and imipramine.

  PMID:1532532 · one of two readings recorded this

• Equivalence of efficacy (meta-analysis and equivalence tests)

  no effect

  The application of various techniques for the analysis of equivalence data suggests that trazodone and imipramine are of approximately equivalent efficacy

  PMID:1532532 · one of two readings recorded this

• Statistical power of the individual trials

  unclear

  the statistical power of most of them was less than 50% and often less than 10%

  PMID:1532532 · one of two readings recorded this

• effort-related arousal threshold in obstructive sleep apnoea, end-tidal CO2 tension at arousal and oesophageal pressure swing by oesophageal balloon, trazodone 100 mg versus placebo

  increases

  Not recorded as a finding: this platform holds no node for the endpoint

  Trazodone at 100 mg increased the effort-related arousal threshold in response to hypercapnia in obstructive sleep apnoea patients and allowed them to tolerate higher CO(2) levels.

  PMID:18256066 · one of two readings recorded this

• effort-related arousal threshold in obstructive sleep apnoea: end-tidal CO2 tension at induced arousal and oesophageal pressure swing before arousal, on CPAP, trazodone 100 mg versus placebo (crossover)

  increases, arousals at PETCO2 7.30+/-0.57 versus 6.62+/-0.64 kPa on trazodone versus placebo

  Not recorded as a finding: this platform holds no node for the endpoint

  During trazodone nights, compared with placebo nights, the arousals occurred at a higher P(ET,CO(2)) level (mean+/-sd 7.30+/-0.57 versus 6.62+/-0.64 kPa (54.9+/-4.3 versus 49.8+/-4.8 mmHg), respectively).

  PMID:18256066 · one of two readings recorded this

• End-tidal CO2 tension at arousal

  increases

  During trazodone nights, compared with placebo nights, the arousals occurred at a higher P(ET,CO(2)) level (mean+/-sd 7.30+/-0.57 versus 6.62+/-0.64 kPa (54.9+/-4.3 versus 49.8+/-4.8 mmHg), respectively)

  PMID:18256066 · one of two readings recorded this

• Maximal oesophageal pressure swing before arousal (CO2-induced arousals)

  increases

  When arousals were triggered by increasing inspired CO(2) level, the maximal oesophageal pressure swing was greater (19.4+/-4.0 versus 13.1+/-4.9 cm H(2)O)

  PMID:18256066 · one of two readings recorded this

• Maximal oesophageal pressure swing before arousal (CPAP-drop-induced arousals)

  no effect

  When arousals were induced by stepwise CPAP drops, the maximal oesophageal pressure swings before the arousals did not differ

  PMID:18256066 · one of two readings recorded this

• Oesophageal pressure nadir before arousal (CO2-induced arousals)

  decreases

  the oesophageal pressure nadir before the arousals was lower (-5.1+/-4.7 versus -0.38+/-4.2 cm H(2)O) with trazodone

  PMID:18256066 · one of two readings recorded this

• Attendance at Alcoholics Anonymous at 1-month follow-up

  no effect, p = 0.09

  the trazodone group tended to be more likely to attend Alcoholics Anonymous (Odd Ratio [OR], 1.91; 95% CI, 0.91, 4.03; P=0.09)

  PMID:18616688 · one of two readings recorded this

• Baseline commitment to abstinence

  no effect

  The study conditions did not differ in their rated baseline commitment to abstinence (mean ± standard deviation, 5.54 ± 1.23 and 5.58 ± 0.92 for the trazodone and placebo groups, respectively)

  PMID:18616688 · one of two readings recorded this

• Baseline proportion of days abstinent by first-month adherence

  decreases, p = 0.02

  Participants who reported less than full adherence with study medication in the first month had had fewer days abstinent at baseline than those who reported 100% adherence (unstandardized β; −0.12; 95% CI, −0.22 to −0.02; P=0.02)

  PMID:18616688 · one of two readings recorded this

• Complete abstinence at 6-month follow-up

  no effect, p = 0.3

  only 9.1% of the trazodone group and 14.1% of the placebo group achieved complete abstinence at the 6-month follow-up (adjusted OR, 0.60; 95% CI, 0.23, 1.56; P=0.30)

  PMID:18616688 · one of two readings recorded this

• Days of psychosocial intervention at 1-month follow-up

  no effect

  the two groups did not differ in the mean number of days of psychosocial intervention at the 1-month follow up (5.55 ± 6.23 and 5.55 ± 4.35 for the trazodone and placebo groups, respectively)

  PMID:18616688 · one of two readings recorded this

• global sleep quality over the past month on the Pittsburgh Sleep Quality Index (PSQI), trazodone 50-150 mg at bedtime versus placebo for 12 weeks after alcohol detoxification; also proportion of days abstinent and drinks per drinking day by calendar method

  increases, Cohen's d -0.50 baseline to 1 month and -0.93 baseline to 3 months, sleep quality improved more on trazodone

  Not recorded as a finding: another reason, stated per paper

  Sleep quality improved more for the trazodone group than the placebo group at the 1- and 3-month follow-ups, with a moderate effect size from baseline to the 1-month assessment (Cohen's d, −0.50) and a large effect from baseline to the 3-month follow-up (Cohen's d, −0.93).

  PMID:18616688 · one of two readings recorded this

• Mental health status (SF-12), change between groups through three months

  increases

  Trazodone similarly improved mental health status modestly from baseline through three months (Cohen's d, −0.18)

  PMID:18616688 · one of two readings recorded this

• Number of drinks per drinking day, change between groups

  increases

  by the 6-month assessment, the trazodone group had a greater increase relative to the placebo group in the number of drinks per drinking day (Cohen's d, 0.41)

  PMID:18616688 · one of two readings recorded this

• Number of pills per day over first 4 weeks (mixed linear regression)

  no effect, p = 0.27

  In a mixed linear regression model the number of pills per day increased similarly in both groups (unstandardized β, 0.01; 95% CI, −0.01 to 0.03; P=0.27)

  PMID:18616688 · one of two readings recorded this

• Pittsburgh Sleep Quality Index, change between groups

  decreases

  with a moderate effect size from baseline to the 1-month assessment (Cohen's d, −0.50) and a large effect from baseline to the 3-month follow-up (Cohen's d, −0.93)

  PMID:18616688 · one of two readings recorded this

• Pittsburgh Sleep Quality Index, change between groups

  decreases

  with a moderate effect size from baseline to the 1-month assessment (Cohen's d, −0.50) and a large effect from baseline to the 3-month follow-up (Cohen's d, −0.93)

  PMID:18616688 · one of two readings recorded this

• Proportion of days abstinent, adherence by treatment interaction

  modulates, p = 0.001, n = 120

  Significant interactions emerged for proportion of days abstinent (unstandardized β, 0.03; 95% CI, 0.01 to 0.04; P=0.001; N=120) and sleep quality (unstandardized β, −0.20; 95% CI, −0.39 to −0.02; P=0.029; N=120)

  PMID:18616688 · one of two readings recorded this

• Proportion of days abstinent, change between groups

  decreases

  effect sizes for the estimated mean difference between groups in the change in the proportion of days abstinent were moderate from baseline to 1-month (Cohen's d, −0.22), 3-month (Cohen's d, −0.50) and 6-month (Cohen's d, −0.51) follow-up assessments

  PMID:18616688 · one of two readings recorded this

• Proportion of days abstinent, change between groups

  decreases

  effect sizes for the estimated mean difference between groups in the change in the proportion of days abstinent were moderate from baseline to 1-month (Cohen's d, −0.22), 3-month (Cohen's d, −0.50) and 6-month (Cohen's d, −0.51) follow-up assessments

  PMID:18616688 · one of two readings recorded this

• Proportion of days abstinent, change between groups

  decreases

  effect sizes for the estimated mean difference between groups in the change in the proportion of days abstinent were moderate from baseline to 1-month (Cohen's d, −0.22), 3-month (Cohen's d, −0.50) and 6-month (Cohen's d, −0.51) follow-up assessments

  PMID:18616688 · one of two readings recorded this

• Proportion of heavy drinking days, change between groups

  decreases

  compared to placebo, the trazodone group showed a smaller decrease in the proportion of heavy drinking days through the 3-month follow-up (Cohen's d, −0.53)

  PMID:18616688 · one of two readings recorded this

• Serum gamma-glutamyltransferase by self-reported drinking status

  decreases, p = 0.07

  Participants reporting abstinence in the prior two weeks had a mean GGT of 56.0 ± 71.0 compared with 129.0 ± 171.6 for those reporting any drinking (P=0.07)

  PMID:18616688 · one of two readings recorded this

• Sleep quality, adherence by treatment interaction

  modulates, p = 0.029, n = 120

  Significant interactions emerged for proportion of days abstinent (unstandardized β, 0.03; 95% CI, 0.01 to 0.04; P=0.001; N=120) and sleep quality (unstandardized β, −0.20; 95% CI, −0.39 to −0.02; P=0.029; N=120)

  PMID:18616688 · one of two readings recorded this

• Composite equilibrium score

  decreases, p = 0.037

  Composite equilibrium scores were significantly lower with trazodone than with placebo (main effect, F(1,14)=5.34, post hoc t=2.3, p=0.037; Table 1)

  PMID:21623982 · one of two readings recorded this

• Consonant trigram recall (36 second delay)

  decreases, p = 0.001

  consonant trigram recall (main effect, F(1,15)=17.3, post hoc t=4.2, p<0.001; Table 1)

  PMID:21623982 · one of two readings recorded this

• Long-term storage on Selective Reminding Test

  decreases, p = 0.037

  Trazodone significantly decreased long-term storage on the SRT (main effect, F(1,15)=5.01, p=0.037; post hoc t=2.2, p=0.041; Table 1)

  PMID:21623982 · one of two readings recorded this

• Lower body muscle endurance (total stands)

  no effect

  There were no significant main effects or drug-time interactions on lower body muscle endurance

  PMID:21623982 · one of two readings recorded this

• Mean arm lifts, Day 1 versus Day 7

  increases, p = 0.002

  Although mean (±SD) arm lifts increased from Day 1 (24±6) to Day 7 (26±7; main effect of time, F(1,15)=14.12, post hoc t=3.8, p=0.002), trazodone significantly decreased arm lifts across days (main effect of drug, F(1,15)=5.98, post hoc t=2.4, p=0.027; Table 1)

  PMID:21623982 · one of two readings recorded this

• Mean arm lifts

  decreases, p = 0.027

  Although mean (±SD) arm lifts increased from Day 1 (24±6) to Day 7 (26±7; main effect of time, F(1,15)=14.12, post hoc t=3.8, p=0.002), trazodone significantly decreased arm lifts across days (main effect of drug, F(1,15)=5.98, post hoc t=2.4, p=0.027; Table 1)

  PMID:21623982 · one of two readings recorded this

• MSLT mean sleep latency

  increases, p = 0.033

  A significant interaction of drug and time on MSLT latency (F(1,15)=4.64, p=0.048) was due to longer mean latencies on Day 7 with trazodone than with placebo (post hoc t=2.3, p=0.033; Table 1)

  PMID:21623982 · one of two readings recorded this

• REM latency

  no effect

  There were no statistically significant main effects or drug-time interactions on sleep latency, REM latency, WASO, Stage 2 minutes, Stage 2%, REM minutes, REM%, SWS%, or sleep efficiency

  PMID:21623982 · one of two readings recorded this

• Simulated driving errors

  no effect

  There were no significant main effects and no drug-time interactions on driving errors or speeding

  PMID:21623982 · one of two readings recorded this

• Simulated driving time speeding

  no effect

  There were no significant main effects and no drug-time interactions on driving errors or speeding

  PMID:21623982 · one of two readings recorded this

• Sleep efficiency

  no effect

  There were no statistically significant main effects or drug-time interactions on sleep latency, REM latency, WASO, Stage 2 minutes, Stage 2%, REM minutes, REM%, SWS%, or sleep efficiency

  PMID:21623982 · one of two readings recorded this

• Sleep latency

  no effect

  There were no statistically significant main effects or drug-time interactions on sleep latency, REM latency, WASO, Stage 2 minutes, Stage 2%, REM minutes, REM%, SWS%, or sleep efficiency

  PMID:21623982 · one of two readings recorded this

• Slow wave sleep minutes

  increases, p = 0.007

  On Day 7, there were significantly more SWS minutes with trazodone than with placebo (interaction F(1,15)=4.92, post hoc t=2.9, post hoc p=0.007, Table 1)

  PMID:21623982 · one of two readings recorded this

• Stage 1 sleep minutes, Day 1 to Day 7

  decreases, p = 0.017

  Stage 1 minutes decreased from Day 1 to Day 7, regardless of drug (main effect of time, F(1,15)=7.17, post hoc t=2.7, p=0.017, Table 1)

  PMID:21623982 · one of two readings recorded this

• Stage 1 sleep minutes

  decreases, p = 0.007

  Trazodone (main effect) significantly reduced total awakenings (F(1,15)=10.35, post hoc t=3.2, p=0.006), Stage 1 minutes (F(1,15)=9.90, post hoc t=3.1, p=0.007), and Stage 1% (F(1,15)=9.41, post hoc t=3.1, p=0.008, Table 1, Figure 1)

  PMID:21623982 · one of two readings recorded this

• Stage 1 sleep percent of total sleep time

  decreases, p = 0.008

  Trazodone (main effect) significantly reduced total awakenings (F(1,15)=10.35, post hoc t=3.2, p=0.006), Stage 1 minutes (F(1,15)=9.90, post hoc t=3.1, p=0.007), and Stage 1% (F(1,15)=9.41, post hoc t=3.1, p=0.008, Table 1, Figure 1)

  PMID:21623982 · one of two readings recorded this

• total awakenings and Stage 1 sleep on overnight polysomnography; also equilibrium score on dynamic posturography, Selective Reminding Test long-term storage, consonant trigram recall, arm muscle endurance, and MSLT latency, trazodone 50 mg versus placebo for 7 days (crossover)

  decreases, main effect of trazodone on total awakenings F(1,15)=10.35, post hoc t=3.2, p = 0.006

  Not recorded as a finding: this platform holds no node for the endpoint

  Trazodone (main effect) significantly reduced total awakenings (F(1,15)=10.35, post hoc t=3.2, p=0.006), Stage 1 minutes (F(1,15)=9.90, post hoc t=3.1, p=0.007), and Stage 1% (F(1,15)=9.41, post hoc t=3.1, p=0.008, Table 1, Figure 1).

  PMID:21623982 · one of two readings recorded this

• total awakenings and Stage 1 sleep on overnight polysomnography; also slow wave sleep, Multiple Sleep Latency Test, equilibrium, Selective Reminding Test, consonant trigram recall and arm muscle endurance, trazodone 50 mg versus placebo

  decreases, main effect of trazodone on total awakenings F(1,15)=10.35, p = 0.006

  Not recorded as a finding: this platform holds no node for the endpoint

  Trazodone (main effect) significantly reduced total awakenings (F(1,15)=10.35, post hoc t=3.2, p=0.006), Stage 1 minutes (F(1,15)=9.90, post hoc t=3.1, p=0.007), and Stage 1% (F(1,15)=9.41, post hoc t=3.1, p=0.008, Table 1, Figure 1).

  PMID:21623982 · one of two readings recorded this

• Total awakenings

  decreases, p = 0.006

  Trazodone (main effect) significantly reduced total awakenings (F(1,15)=10.35, post hoc t=3.2, p=0.006), Stage 1 minutes (F(1,15)=9.90, post hoc t=3.1, p=0.007), and Stage 1% (F(1,15)=9.41, post hoc t=3.1, p=0.008, Table 1, Figure 1)

  PMID:21623982 · one of two readings recorded this

• Visual analog scale rating of difficulty sleeping

  decreases, p = 0.012

  There was a main effect of trazodone on ratings of “difficulty sleeping” (F(1,15)=8.16, post hoc t=2.9, p=0.012; Table 1)

  PMID:21623982 · one of two readings recorded this

• Visual analog scale rating of restless, over time

  decreases, p = 0.011

  Regardless of drug, ratings of “restless” decreased over time (main effect, F(1,15)=8.42, post hoc t=2.9, p=0.011; Table 1)

  PMID:21623982 · one of two readings recorded this

• Wake after sleep onset (WASO)

  no effect

  There were no statistically significant main effects or drug-time interactions on sleep latency, REM latency, WASO, Stage 2 minutes, Stage 2%, REM minutes, REM%, SWS%, or sleep efficiency

  PMID:21623982 · one of two readings recorded this

• Benzodiazepine use on toxicology the morning after PSG

  no effect, p = 0.39

  did not differ significantly with respect to use of opioids (χ2 = 0.86, p =.35), cocaine (χ2 = 0.8, p =.35), cannabinoids (χ2 = 0.74, p =.39), or benzodiazepines (χ2 = 0.75, p =.39)

  PMID:21798674 · one of two readings recorded this

• Cannabinoid use on toxicology the morning after PSG

  no effect, p = 0.39

  did not differ significantly with respect to use of opioids (χ2 = 0.86, p =.35), cocaine (χ2 = 0.8, p =.35), cannabinoids (χ2 = 0.74, p =.39), or benzodiazepines (χ2 = 0.75, p =.39)

  PMID:21798674 · one of two readings recorded this

• Change in daily frequency of alcohol use, baseline to 1 month

  no effect, p = 0.61

  We also found no significant between group differences with respect to change in daily frequency of alcohol use (t132 = −0.51, p =.61), opioids (t132 = 0.16, p =.87), cocaine (t132 = −1.06, p =.29), benzodiazepine (t132 = −1.17, p =.24), or cannabis use (t132 = 1.21, p =.23)

  PMID:21798674 · one of two readings recorded this

• Change in daily frequency of benzodiazepine use, baseline to 1 month

  no effect, p = 0.24

  We also found no significant between group differences with respect to change in daily frequency of alcohol use (t132 = −0.51, p =.61), opioids (t132 = 0.16, p =.87), cocaine (t132 = −1.06, p =.29), benzodiazepine (t132 = −1.17, p =.24), or cannabis use (t132 = 1.21, p =.23)

  PMID:21798674 · one of two readings recorded this

• Change in daily frequency of cannabis use, baseline to 1 month

  no effect, p = 0.23

  We also found no significant between group differences with respect to change in daily frequency of alcohol use (t132 = −0.51, p =.61), opioids (t132 = 0.16, p =.87), cocaine (t132 = −1.06, p =.29), benzodiazepine (t132 = −1.17, p =.24), or cannabis use (t132 = 1.21, p =.23)

  PMID:21798674 · one of two readings recorded this

• Change in daily frequency of cocaine use, baseline to 1 month

  no effect, p = 0.29

  We also found no significant between group differences with respect to change in daily frequency of alcohol use (t132 = −0.51, p =.61), opioids (t132 = 0.16, p =.87), cocaine (t132 = −1.06, p =.29), benzodiazepine (t132 = −1.17, p =.24), or cannabis use (t132 = 1.21, p =.23)

  PMID:21798674 · one of two readings recorded this

• Change in daily frequency of opioid use, baseline to 1 month

  no effect, p = 0.87

  We also found no significant between group differences with respect to change in daily frequency of alcohol use (t132 = −0.51, p =.61), opioids (t132 = 0.16, p =.87), cocaine (t132 = −1.06, p =.29), benzodiazepine (t132 = −1.17, p =.24), or cannabis use (t132 = 1.21, p =.23)

  PMID:21798674 · one of two readings recorded this

• Cocaine use on toxicology the morning after PSG

  no effect, p = 0.35

  did not differ significantly with respect to use of opioids (χ2 = 0.86, p =.35), cocaine (χ2 = 0.8, p =.35), cannabinoids (χ2 = 0.74, p =.39), or benzodiazepines (χ2 = 0.75, p =.39)

  PMID:21798674 · one of two readings recorded this

• Decreased appetite (symptom checklist)

  increases, p = 0.04

  Between baseline and 1-month, participants randomized to trazodone were significantly more likely to report increased thirst or dry mouth (p=.001) and decreased appetite (p=.04)

  PMID:21798674 · one of two readings recorded this

• Increased thirst or dry mouth (symptom checklist)

  increases, p = 0.001

  Between baseline and 1-month, participants randomized to trazodone were significantly more likely to report increased thirst or dry mouth (p=.001) and decreased appetite (p=.04)

  PMID:21798674 · one of two readings recorded this

• Increased thirst or dry mouth (symptom checklist)

  increases, p = 0.02

  Significant (p =.02) differences with respect to increased thirst or dry mouth only persisted to the 3-month follow-up

  PMID:21798674 · one of two readings recorded this

• Number of awakenings per night (morning survey), reduction baseline to 1 month

  decreases, p = 0.06

  trazodone recipients reported an average reduction of.89 awakenings per night compared with a reduction of.46 among placebo recipients (t91 = −1.90, p =.06); the corresponding standardized effect was.401

  PMID:21798674 · one of two readings recorded this

• Number of awakenings per night (sleep log), decrease baseline to 1 month

  no effect, p = 0.16

  The average number of awakenings decreased 1.23 times per night for the trazodone group compared with.72 times per night for the placebo group (t51 = −1.42, p =.16)

  PMID:21798674 · one of two readings recorded this

• Opioid use on toxicology the morning after PSG

  no effect, p = 0.35

  did not differ significantly with respect to use of opioids (χ2 = 0.86, p =.35), cocaine (χ2 = 0.8, p =.35), cannabinoids (χ2 = 0.74, p =.39), or benzodiazepines (χ2 = 0.75, p =.39)

  PMID:21798674 · one of two readings recorded this

• PSQI global score reduction baseline to 1 month

  decreases, p = 0.07

  Between group differences in the reduction in global PSQI scores were substantively larger (d = −.39) and marginally significant (t91 = −1.87, p =.07); mean reductions were 3.0 and 4.5 among those randomized to placebo and trazodone, respectively

  PMID:21798674 · one of two readings recorded this

• PSQI total score, change baseline to 1 month

  no effect, p = 0.145

  between baseline and 1-month, mean PSQI scores decreased 2.9 and 3.9 points among those randomized to placebo and trazodone, respectively; the difference in mean change was not significant (p =.145)

  PMID:21798674 · one of two readings recorded this

• PSQI total score during follow-up (mixed effects linear regression)

  no effect, p = 0.102

  The coefficient giving the effect of trazodone on mean PSQI scores during follow-up was not statistically significant (b = −.82, z = −1.63, p =.102)

  PMID:21798674 · one of two readings recorded this

• Restfulness rating (morning survey), baseline to 1 month

  increases, p = 0.02

  Those randomized to trazodone also reported significantly improved (t91 = −2.37, p =.02) restfulness ratings on the morning survey (d =.50)

  PMID:21798674 · one of two readings recorded this

• Restfulness rating (sleep log), change baseline to 1 month

  no effect, p = 0.069

  the average restfulness rating increased.43 units among those randomized to trazodone but decreased.10 units among placebo recipients (t51 = 1.86, p =.069)

  PMID:21798674 · one of two readings recorded this

• Restfulness rating (sleep logs) at baseline

  increases, p = 0.05

  placebo group participants reported significantly higher mean sleep quality ratings on the morning survey (t = 2.11, p =.04) and restfulness ratings on the sleep logs (t = 1.96, p =.05) at baseline

  PMID:21798674 · one of two readings recorded this

• Self-reported caffeine use in the 4 hours prior to PSG

  no effect, p = 0.92

  no significant differences were found with respect to self-reported caffeine (χ2 = 0.01, p =.92) or cigarette use (χ2 = 1.28, p =.26) in the 4 hours prior to the PSG

  PMID:21798674 · one of two readings recorded this

• Self-reported cigarette use in the 4 hours prior to PSG

  no effect, p = 0.26

  no significant differences were found with respect to self-reported caffeine (χ2 = 0.01, p =.92) or cigarette use (χ2 = 1.28, p =.26) in the 4 hours prior to the PSG

  PMID:21798674 · one of two readings recorded this

• Sleep quality rating (morning survey) at baseline

  increases, p = 0.04

  placebo group participants reported significantly higher mean sleep quality ratings on the morning survey (t = 2.11, p =.04) and restfulness ratings on the sleep logs (t = 1.96, p =.05) at baseline

  PMID:21798674 · one of two readings recorded this

• Sub-threshold PSQI score at follow-up (mixed-effects logistic regression)

  no effect, p = 0.101

  the intervention arms did not differ significantly with respect to the likelihood of having sub-threshold PSQI scores at follow-up (OR = 2.10, z = 1.64, p =.101)

  PMID:21798674 · one of two readings recorded this

• Subjective total sleep time (morning survey), change baseline to 1 month

  increases, p = 0.05

  As reported on the morning survey, subjective total sleep time increased by about 45.5 minutes among those receiving trazodone compared to 9.8 minutes in the placebo group (t = −1.99, p =.05); the standardized effect size was.373

  PMID:21798674 · one of two readings recorded this

• Subjective total sleep time (morning survey), change baseline to 1 month

  no effect, p = 0.14

  The adjusted effect of trazodone on change in total sleep time, as reported on the morning survey, was not significant (b = 0.48, t = −1.49, p =.14)

  PMID:21798674 · one of two readings recorded this

• subjective total sleep time on morning survey, minutes, change baseline to 1 month

  increases, 45.5 minutes on trazodone vs 9.8 minutes on placebo, p = 0.05

  Not recorded as a finding: borderline p = .05 unadjusted and not significant after adjustment (p = .14) in the next sentence, so a direction would overstate it; also 1 of 23 comparisons significant without multiplicity adjustment

  As reported on the morning survey, subjective total sleep time increased by about 45.5 minutes among those receiving trazodone compared to 9.8 minutes in the placebo group (t = −1.99, p =.05); the standardized effect size was.373.

  PMID:21798674 · one of two readings recorded this

• subjective total sleep time on the morning survey, minutes, baseline to one month

  increases, increased about 45.5 minutes with trazodone versus 9.8 minutes with placebo, p = 0.05

  Not recorded as a finding: borderline p of .05 and a self-report morning survey rather than the PSG, actigraphy or diary measurements the total-sleep-time node names; the paper states only 1 of 23 comparisons was significant

  As reported on the morning survey, subjective total sleep time increased by about 45.5 minutes among those receiving trazodone compared to 9.8 minutes in the placebo group (t = −1.99, p =.05); the standardized effect size was.373.

  PMID:21798674 · one of two readings recorded this

• apnea/hypopnea index (AHI) on polysomnography, and non-REM arousal threshold by epiglottic catheter, trazodone 100 mg versus placebo

  decreases, 38.7 vs. 28.5 events/h, p = 0.041

  Not recorded as a finding: this platform holds no node for the endpoint

  Compared with placebo, trazodone resulted in a significant reduction in AHI (38.7 vs. 28.5 events/h, P = 0.041), without worsening oxygen saturation or respiratory event duration.

  PMID:25719754 · one of two readings recorded this

• apnea/hypopnea index (AHI) on standard polysomnogram, and non-REM arousal threshold by epiglottic catheter nadir pressure, trazodone 100 mg versus placebo in OSA

  decreases, AHI 38.7 vs. 28.5 events/h on placebo versus trazodone, p = 0.041

  Not recorded as a finding: this platform holds no node for the endpoint

  Compared with placebo, trazodone resulted in a significant reduction in AHI (38.7 vs. 28.5 events/h, P = 0.041), without worsening oxygen saturation or respiratory event duration.

  PMID:25719754 · one of two readings recorded this

• Apnea/hypopnea index

  decreases, p = 0.041

  Compared with placebo, trazodone resulted in a significant reduction in AHI (38.7 vs. 28.5 events/h, P = 0.041)

  PMID:25719754 · one of two readings recorded this

• Non-REM arousal threshold

  no effect, p = 0.51

  Trazodone was not associated with a significant change in the non-REM arousal threshold (-20.3 vs. -19.3 cm H2O, P = 0.51) compared with placebo

  PMID:25719754 · one of two readings recorded this

• Time in N1 sleep

  decreases, p = 0.052

  responders to trazodone spent less time in N1 sleep (20.1% placebo vs. 9.0% trazodone, P = 0.052)

  PMID:25719754 · one of two readings recorded this

• CGI-G score at final visit

  increases

  The mean CGI-G score at the final visit showed a statistically significant difference in favor of venlafaxine both in the ITT and PP population

  PMID:31972628 · one of two readings recorded this

• CGI-S change from baseline at final visit

  increases

  The change in the mean CGI-S score from baseline showed a statistically significant difference in favor of venlafaxine at the final visit in the ITT but not in the PP population

  PMID:31972628 · one of two readings recorded this

• CGI-S change from baseline at final visit

  no effect

  The change in the mean CGI-S score from baseline showed a statistically significant difference in favor of venlafaxine at the final visit in the ITT but not in the PP population

  PMID:31972628 · one of two readings recorded this

• ECG parameter changes from screening (QTcF, QT, RR, QRS) at final visit

  unclear

  At the final visit, both groups were significantly different in the changes from screening in the following parameters: QTcF, QT, RR, and QRS

  PMID:31972628 · one of two readings recorded this

• HAM-D-17 sleep disturbance factor, change from baseline

  unclear

  Trazodone demonstrated a statistically significant difference in HAM-D-17 sleep disturbance scores from baseline in all visits in the PP population

  PMID:31972628 · one of two readings recorded this

• HAM-D-17 total score at baseline

  The mean baseline severity of illness measured with HAM-D-17 total score was at least moderate for both ITT and PP populations (ITT: trazodone OAD 23.7 ± 3.42, venlafaxine XR 23.8 ± 3.93; PP: trazodone OAD 23.9 ± 3.41, venlafaxine XR 24.1 ± 4.02)

  PMID:31972628 · one of two readings recorded this

• HAM-D-17 total score at baseline

  The mean baseline severity of illness measured with HAM-D-17 total score was at least moderate for both ITT and PP populations (ITT: trazodone OAD 23.7 ± 3.42, venlafaxine XR 23.8 ± 3.93; PP: trazodone OAD 23.9 ± 3.41, venlafaxine XR 24.1 ± 4.02)

  PMID:31972628 · one of two readings recorded this

• HAM-D-17 total score at final visit

  The severity of depression in both groups decreased from moderate to mild, based on the mean HAM-D-17 total score at the final visit (ITT: trazodone 10.8 ± 6.49, venlafaxine 9.1 ± 6.00; PP: trazodone 8.5 ± 4.97, venlafaxine 7.7 ± 5.07)

  PMID:31972628 · one of two readings recorded this

• HAM-D-17 total score at final visit

  The severity of depression in both groups decreased from moderate to mild, based on the mean HAM-D-17 total score at the final visit (ITT: trazodone 10.8 ± 6.49, venlafaxine 9.1 ± 6.00; PP: trazodone 8.5 ± 4.97, venlafaxine 7.7 ± 5.07)

  PMID:31972628 · one of two readings recorded this

• HAM-D-17 total score, between-treatment difference in change at final visit

  increases, p = 0.01

  The difference between treatments was on average 1.6 with the 95% CI ranging from 0.4 to 2.9 in the ITT population (P = 0.010)

  PMID:31972628 · one of two readings recorded this

• HAM-D-17 total score, between-treatment difference in change at final visit

  no effect, p = 0.056

  1.1 with the 95% CI ranging from –0.0 to 2.2 in the PP population (P = 0.056)

  PMID:31972628 · one of two readings recorded this

• HAM-D-17 total score, change from baseline at final visit

  decreases

  Both treatments showed good efficacy in terms of reduction of mean ± SD HAM-D-17 total score at the final visit compared to baseline (ITT: trazodone –12.9 ± 6.82, venlafaxine –14.7 ± 6.56; PP: trazodone –15.4 ± 5.32, venlafaxine –16.4 ± 5.39)

  PMID:31972628 · one of two readings recorded this

• HAM-D-17 total score, change from baseline at final visit

  decreases

  Both treatments showed good efficacy in terms of reduction of mean ± SD HAM-D-17 total score at the final visit compared to baseline (ITT: trazodone –12.9 ± 6.82, venlafaxine –14.7 ± 6.56; PP: trazodone –15.4 ± 5.32, venlafaxine –16.4 ± 5.39)

  PMID:31972628 · one of two readings recorded this

• HAM-D-17 total score, change from baseline at final visit

  decreases

  Both treatments showed good efficacy in terms of reduction of mean ± SD HAM-D-17 total score at the final visit compared to baseline (ITT: trazodone –12.9 ± 6.82, venlafaxine –14.7 ± 6.56; PP: trazodone –15.4 ± 5.32, venlafaxine –16.4 ± 5.39)

  PMID:31972628 · one of two readings recorded this

• HAM-D-17 total score, change from baseline at final visit

  decreases

  Both treatments showed good efficacy in terms of reduction of mean ± SD HAM-D-17 total score at the final visit compared to baseline (ITT: trazodone –12.9 ± 6.82, venlafaxine –14.7 ± 6.56; PP: trazodone –15.4 ± 5.32, venlafaxine –16.4 ± 5.39)

  PMID:31972628 · one of two readings recorded this

• HAM-D-17 total score reduction, early onset

  increases

  a significantly higher reduction in the mean HAM-D-17 score was observed in the trazodone OAD group after only 7 days of treatment

  PMID:31972628 · one of two readings recorded this

• MADRS total score at final visit

  p = 0.003

  The severity of disease decreased in both arms from moderate to mild, based on the mean MADRS total score at the final visit (ITT: trazodone 12.7 ± 8.58, venlafaxine 10.2 ± 7.02; P = 0.003; PP: trazodone 9.7 ± 6.37, venlafaxine 8.6 ± 5.40)

  PMID:31972628 · one of two readings recorded this

• MADRS total score at final visit

  The severity of disease decreased in both arms from moderate to mild, based on the mean MADRS total score at the final visit (ITT: trazodone 12.7 ± 8.58, venlafaxine 10.2 ± 7.02; P = 0.003; PP: trazodone 9.7 ± 6.37, venlafaxine 8.6 ± 5.40)

  PMID:31972628 · one of two readings recorded this

• QTcF >450 ms or prolongation >60 ms at any visit

  no effect

  Eleven patients in the trazodone OAD group and six patients in the venlafaxine XR group showed QTcF values higher than 450 ms during the study or prolongation higher than 60 ms at any visit with respect to the screening value

  PMID:31972628 · one of two readings recorded this

• Remission rate (HAM-D score <= 7)

  decreases, p = 0.0068

  clinical remission occurred in 37.7% and 52.0% of trazodone- and venlafaxine-treated patients, respectively (P = 0.0068)

  PMID:31972628 · one of two readings recorded this

• Remission rate (HAM-D score <= 7)

  decreases, p = 0.013

  in the PP population remission occurred in 48.4% and 60.6% of patients, respectively (P = 0.0130)

  PMID:31972628 · one of two readings recorded this

• Responder rate (50% decrease in HAM-D score)

  decreases, p = 0.0396

  The rates of responders with trazodone and venlafaxine were 65.4% and 76.3%, respectively, in the ITT population (P = 0.0396)

  PMID:31972628 · one of two readings recorded this

• Responder rate (50% decrease in HAM-D score)

  no effect, p = 0.2097

  82.8% and 87.4%, respectively, in the PP population (P = 0.2097)

  PMID:31972628 · one of two readings recorded this

• Highest time-matched placebo-adjusted change from baseline QTcF

  increases

  24.5 ms (upper CI limit 28.7 ms) at 1 hour postdose for the 140‐mg dose

  PMID:32488885 · one of two readings recorded this

• Highest time-matched placebo-adjusted change from baseline QTcF

  increases

  The highest QTcF placebo‐adjusted change from baseline was 7.0 ms (upper CI limit 12.8 ms) at 0.75 hour postdose for the 20‐mg dose

  PMID:32488885 · one of two readings recorded this

• Highest time-matched placebo-adjusted change from baseline QTcF

  increases

  16.9 ms (upper CI limit 21.3 ms) at 0.75 hour postdose for the 60‐mg dose

  PMID:32488885 · one of two readings recorded this

• placebo-adjusted change from baseline in Fridericia-corrected QT interval (ΔΔQTcF) against plasma trazodone concentration, continuous 12-lead ECG; also heart rate, PR and QRS intervals

  increases, predicted ΔΔQTcF at mean Cmax approximately 4.5 ms (20 mg), 12.3 ms (60 mg), 19.8 ms (140 mg)

  Not recorded as a finding: this platform holds no node for the endpoint

  The overall predicted placebo‐adjusted and baseline QTcF corrected value at mean Cmax was approximately 4.5 ms (2‐sided 90%CI upper limit 5.3 ms) for the 20‐mg dose, 12.3 ms (2‐sided 90%CI upper limit 13.6 ms) for the 60‐mg dose, and 19.8 ms (2‐sided 90%CI upper limit 22.1 ms) for the 140‐mg dose (Table 2).

  PMID:32488885 · one of two readings recorded this

• Placebo-adjusted change from baseline QTcF (ΔΔQTcF) at mean Cmax, concentration-QTc model

  increases

  the predicted effect of moxifloxacin on placebo‐adjusted and baseline‐corrected QTcF at the mean Cmax was 15.2 ms (2‐sided 90%CI 13.6‐16.9 ms)

  PMID:32488885 · one of two readings recorded this

• Placebo-adjusted change from baseline QTcF (ΔΔQTcF) at mean Cmax, concentration-QTc model

  increases

  19.8 ms (2‐sided 90%CI upper limit 22.1 ms) for the 140‐mg dose

  PMID:32488885 · one of two readings recorded this

• Placebo-adjusted change from baseline QTcF (ΔΔQTcF) at mean Cmax, concentration-QTc model

  increases

  approximately 4.5 ms (2‐sided 90%CI upper limit 5.3 ms) for the 20‐mg dose

  PMID:32488885 · one of two readings recorded this

• Placebo-adjusted change from baseline QTcF (ΔΔQTcF) at mean Cmax, concentration-QTc model

  increases

  12.3 ms (2‐sided 90%CI upper limit 13.6 ms) for the 60‐mg dose

  PMID:32488885 · one of two readings recorded this

• Placebo-adjusted heart rate at mean Cmax

  no effect

  2.76 bpm (1‐sided 95%CI 1.2‐4.4) for the 140‐mg dose

  PMID:32488885 · one of two readings recorded this

• Placebo-adjusted heart rate at mean Cmax

  no effect

  was 1.45 bpm (1‐sided 95%CI 0.9‐2.1) for the 20‐mg dose

  PMID:32488885 · one of two readings recorded this

• Placebo-adjusted heart rate at mean Cmax

  no effect

  2.12 bpm (1‐sided 95%CI 1.3‐3.0) for the 60‐mg dose

  PMID:32488885 · one of two readings recorded this

• Placebo-adjusted PR interval at mean Cmax

  no effect

  was –7.4 ms (1‐sided 95%CI –9.3 to 5.4)

  PMID:32488885 · one of two readings recorded this

• Placebo-adjusted QRS interval at mean Cmax

  no effect

  was 0.115 ms (1‐sided 95%CI 0.115‐0.70)

  PMID:32488885 · one of two readings recorded this

• Slope of plasma concentration versus placebo-adjusted QTcF

  increases

  was positive (4.24 ms/[μg/mL])

  PMID:32488885 · one of two readings recorded this

• Slope of plasma concentration versus placebo-adjusted QTcF

  increases

  The slope (SE) of the plasma‐concentration effect on placebo‐adjusted and baseline‐corrected QTcF for trazodone was 9.65 ms/[μg/mL] (SE 1.1094; P‐value.000)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  0.0833 | –3.3 (–7.8 to 1.1) | –2.3 (–6.7 to 2.1) | 0.8 (–2.7 to 4.4) | 2.5 (–1.9 to 7.0)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  0.1666 | –1.2 (–6.2 to 3.8) | 0.3 (–4.1 to 4.6) | 0.5 (–3.0 to 4.0) | 1.6 (–1.9 to 5.0)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  0.3333 | –0.2 (–5.4 to 5.0) | 4.8 (–0.4 to 10.0) | 11.6 (7.8–15.5) | 1.0 (–3.5 to 5.5)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  0.5 | 2.1 (–0.3 to 4.6) | 11.9 (8.6–15.3) | 20.2 (16.4–23.9) | 6.7 (2.6–10.8)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  0.75 | 7.0 (1.2–12.8) | 16.9 (–12.6 to 21.3) | 21.4 (16.3–26.5) | 13.0 (8.8–17.2)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  1.5 | 5.0 (0.6–9.5) | 14.4 (–10.0 to 18.8) | 19.6 (15.3–24.0) | 12.2 (7.5–16.9)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  1 | 6.6 (1.5–11.7) | 11.4 (–6.3 to 16.5) | 24.5 (20.3–28.7) | 11.9 (8.3–15.6)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  12 | 0.6 (–4.7 to 5.8) | 6.4 (1.7–11.0) | 7.9 (4.3–11.6) | 10.0 (5.4–14.7)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  16 | –3.3 (–6.9 to 0.3) | –1.4 (–5.6 to 2.7) | –0.7 (–5.2 to 3.8) | 8.6 (4.6–12.6)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  2 | 3.5 (0.5–6.5) | 8.8 (4.2–13.4) | 17.1 (13.4–20.8) | 14.5 (9.7–19.4)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  24 | 1.8 (–3.5 to 7.1) | 2.0 (–3.0 to 6.9) | 1.7 (–1.4 to 4.8) | 7.1 (3.6–10.6)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  3 | 1.7 (–2.7 to 6.1) | 6.1 (1.9–10.2) | 14.5 (7.6–21.5) | 13.9 (8.9–19.0)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  4 | 3.2 (–2.3 to 8.6) | 7.9 (4.3–11.5) | 12.8 (8.5–17.1) | 15.0 (10.3–19.7)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  6 | –0.2 (–4.8 to 4.3) | 2.2 (–1.8 to 6.2) | 6.7 (2.3–11.2) | 9.1 (5.0–13.2)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  8 | 1.2 (–2.3 to 4.6) | –0.4 (–3.4 to 2.7) | 5.8 (0.9–10.7) | 10.1 (6.6–13.7)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  0.0833 | –3.3 (–7.8 to 1.1) | –2.3 (–6.7 to 2.1) | 0.8 (–2.7 to 4.4) | 2.5 (–1.9 to 7.0)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  0.1666 | –1.2 (–6.2 to 3.8) | 0.3 (–4.1 to 4.6) | 0.5 (–3.0 to 4.0) | 1.6 (–1.9 to 5.0)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  0.3333 | –0.2 (–5.4 to 5.0) | 4.8 (–0.4 to 10.0) | 11.6 (7.8–15.5) | 1.0 (–3.5 to 5.5)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  0.5 | 2.1 (–0.3 to 4.6) | 11.9 (8.6–15.3) | 20.2 (16.4–23.9) | 6.7 (2.6–10.8)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  0.75 | 7.0 (1.2–12.8) | 16.9 (–12.6 to 21.3) | 21.4 (16.3–26.5) | 13.0 (8.8–17.2)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  1.5 | 5.0 (0.6–9.5) | 14.4 (–10.0 to 18.8) | 19.6 (15.3–24.0) | 12.2 (7.5–16.9)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  1 | 6.6 (1.5–11.7) | 11.4 (–6.3 to 16.5) | 24.5 (20.3–28.7) | 11.9 (8.3–15.6)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  12 | 0.6 (–4.7 to 5.8) | 6.4 (1.7–11.0) | 7.9 (4.3–11.6) | 10.0 (5.4–14.7)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  16 | –3.3 (–6.9 to 0.3) | –1.4 (–5.6 to 2.7) | –0.7 (–5.2 to 3.8) | 8.6 (4.6–12.6)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  2 | 3.5 (0.5–6.5) | 8.8 (4.2–13.4) | 17.1 (13.4–20.8) | 14.5 (9.7–19.4)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  24 | 1.8 (–3.5 to 7.1) | 2.0 (–3.0 to 6.9) | 1.7 (–1.4 to 4.8) | 7.1 (3.6–10.6)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  3 | 1.7 (–2.7 to 6.1) | 6.1 (1.9–10.2) | 14.5 (7.6–21.5) | 13.9 (8.9–19.0)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  4 | 3.2 (–2.3 to 8.6) | 7.9 (4.3–11.5) | 12.8 (8.5–17.1) | 15.0 (10.3–19.7)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  6 | –0.2 (–4.8 to 4.3) | 2.2 (–1.8 to 6.2) | 6.7 (2.3–11.2) | 9.1 (5.0–13.2)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  8 | 1.2 (–2.3 to 4.6) | –0.4 (–3.4 to 2.7) | 5.8 (0.9–10.7) | 10.1 (6.6–13.7)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  0.0833 | –3.3 (–7.8 to 1.1) | –2.3 (–6.7 to 2.1) | 0.8 (–2.7 to 4.4) | 2.5 (–1.9 to 7.0)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  0.1666 | –1.2 (–6.2 to 3.8) | 0.3 (–4.1 to 4.6) | 0.5 (–3.0 to 4.0) | 1.6 (–1.9 to 5.0)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  0.3333 | –0.2 (–5.4 to 5.0) | 4.8 (–0.4 to 10.0) | 11.6 (7.8–15.5) | 1.0 (–3.5 to 5.5)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  0.5 | 2.1 (–0.3 to 4.6) | 11.9 (8.6–15.3) | 20.2 (16.4–23.9) | 6.7 (2.6–10.8)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  0.75 | 7.0 (1.2–12.8) | 16.9 (–12.6 to 21.3) | 21.4 (16.3–26.5) | 13.0 (8.8–17.2)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  1.5 | 5.0 (0.6–9.5) | 14.4 (–10.0 to 18.8) | 19.6 (15.3–24.0) | 12.2 (7.5–16.9)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  1 | 6.6 (1.5–11.7) | 11.4 (–6.3 to 16.5) | 24.5 (20.3–28.7) | 11.9 (8.3–15.6)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  12 | 0.6 (–4.7 to 5.8) | 6.4 (1.7–11.0) | 7.9 (4.3–11.6) | 10.0 (5.4–14.7)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  16 | –3.3 (–6.9 to 0.3) | –1.4 (–5.6 to 2.7) | –0.7 (–5.2 to 3.8) | 8.6 (4.6–12.6)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  2 | 3.5 (0.5–6.5) | 8.8 (4.2–13.4) | 17.1 (13.4–20.8) | 14.5 (9.7–19.4)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  24 | 1.8 (–3.5 to 7.1) | 2.0 (–3.0 to 6.9) | 1.7 (–1.4 to 4.8) | 7.1 (3.6–10.6)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  3 | 1.7 (–2.7 to 6.1) | 6.1 (1.9–10.2) | 14.5 (7.6–21.5) | 13.9 (8.9–19.0)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  4 | 3.2 (–2.3 to 8.6) | 7.9 (4.3–11.5) | 12.8 (8.5–17.1) | 15.0 (10.3–19.7)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  6 | –0.2 (–4.8 to 4.3) | 2.2 (–1.8 to 6.2) | 6.7 (2.3–11.2) | 9.1 (5.0–13.2)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  8 | 1.2 (–2.3 to 4.6) | –0.4 (–3.4 to 2.7) | 5.8 (0.9–10.7) | 10.1 (6.6–13.7)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  0.0833 | –3.3 (–7.8 to 1.1) | –2.3 (–6.7 to 2.1) | 0.8 (–2.7 to 4.4) | 2.5 (–1.9 to 7.0)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  0.1666 | –1.2 (–6.2 to 3.8) | 0.3 (–4.1 to 4.6) | 0.5 (–3.0 to 4.0) | 1.6 (–1.9 to 5.0)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  0.3333 | –0.2 (–5.4 to 5.0) | 4.8 (–0.4 to 10.0) | 11.6 (7.8–15.5) | 1.0 (–3.5 to 5.5)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  0.5 | 2.1 (–0.3 to 4.6) | 11.9 (8.6–15.3) | 20.2 (16.4–23.9) | 6.7 (2.6–10.8)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  0.75 | 7.0 (1.2–12.8) | 16.9 (–12.6 to 21.3) | 21.4 (16.3–26.5) | 13.0 (8.8–17.2)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  1.5 | 5.0 (0.6–9.5) | 14.4 (–10.0 to 18.8) | 19.6 (15.3–24.0) | 12.2 (7.5–16.9)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  1 | 6.6 (1.5–11.7) | 11.4 (–6.3 to 16.5) | 24.5 (20.3–28.7) | 11.9 (8.3–15.6)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  12 | 0.6 (–4.7 to 5.8) | 6.4 (1.7–11.0) | 7.9 (4.3–11.6) | 10.0 (5.4–14.7)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  16 | –3.3 (–6.9 to 0.3) | –1.4 (–5.6 to 2.7) | –0.7 (–5.2 to 3.8) | 8.6 (4.6–12.6)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  2 | 3.5 (0.5–6.5) | 8.8 (4.2–13.4) | 17.1 (13.4–20.8) | 14.5 (9.7–19.4)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  24 | 1.8 (–3.5 to 7.1) | 2.0 (–3.0 to 6.9) | 1.7 (–1.4 to 4.8) | 7.1 (3.6–10.6)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  3 | 1.7 (–2.7 to 6.1) | 6.1 (1.9–10.2) | 14.5 (7.6–21.5) | 13.9 (8.9–19.0)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  increases

  4 | 3.2 (–2.3 to 8.6) | 7.9 (4.3–11.5) | 12.8 (8.5–17.1) | 15.0 (10.3–19.7)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  6 | –0.2 (–4.8 to 4.3) | 2.2 (–1.8 to 6.2) | 6.7 (2.3–11.2) | 9.1 (5.0–13.2)

  PMID:32488885 · one of two readings recorded this

• Time-matched placebo-adjusted change from baseline QTcF

  no effect

  8 | 1.2 (–2.3 to 4.6) | –0.4 (–3.4 to 2.7) | 5.8 (0.9–10.7) | 10.1 (6.6–13.7)

  PMID:32488885 · one of two readings recorded this

• Insomnia severity index score

  no effect

  there were no differences on insomnia severity index scores between the trazodone and the CBT-I groups

  PMID:32780015 · one of two readings recorded this

• Salivary cortisol, percent change from pretreatment to follow-up

  decreases

  from pretreatment to follow-up (-21.37% vs -5.79%; Cohen's d = 0.284)

  PMID:32780015 · one of two readings recorded this

• Salivary cortisol, percent change from pretreatment to posttreatment

  decreases

  from pretreatment to posttreatment (-36.07% vs -11.70%; Cohen's d = 0.793)

  PMID:32780015 · one of two readings recorded this

• Total sleep time by actigraphy, change at follow-up

  increases, p = 0.012

  at follow-up (50.35 minutes vs -7.56 minutes; P = .012; Cohen's d = 1.725)

  PMID:32780015 · one of two readings recorded this

• Total sleep time by actigraphy, change at posttreatment

  increases, p = 0.051

  Trazodone, but not CBT-I, significantly lengthened total sleep time (when measured with actigraphy) both at posttreatment (51.01 minutes vs -11.73 minutes; P = .051; Cohen's d = 1.383)

  PMID:32780015 · one of two readings recorded this

• total sleep time by actigraphy, salivary cortisol and insomnia severity index, trazodone versus cognitive behavioral therapy for insomnia (CBT-I)

  increases, 51.01 minutes vs -11.73 minutes at posttreatment

  Not recorded as a finding: the comparison was against another active treatment

  Trazodone, but not CBT-I, significantly lengthened total sleep time (when measured with actigraphy) both at posttreatment (51.01 minutes vs -11.73 minutes; P = .051; Cohen's d = 1.383) and at follow-up (50.35 minutes vs -7.56 minutes; P = .012; Cohen's d = 1.725), respectively.

  PMID:32780015 · one of two readings recorded this

• Apnea-hypopnea index (AHI)

  no effect, p = 0.4

  AHI | P = 0.10; I2 = 57% | − 4.21 | − 14.02, 5.59 | 0.84 | 0.40 | 0.558

  PMID:36002579 · one of two readings recorded this

• Daytime drowsiness

  increases, p = 0.02

  Daytime drowsiness (OR = 2.53, 95% CI 1.14–5.64, P = 0.02)

  PMID:36002579 · one of two readings recorded this

• Decreased appetite

  increases, p = 0.02

  decreased appetite (OR = 2.81, 95% CI 1.14–6.92, P = 0.02)

  PMID:36002579 · one of two readings recorded this

• Discontinuation for all causes

  no effect, p = 0.15

  discontinuation for all causes (OR = 0.63, 95% CI 0.33–1.18, P = 0.15)

  PMID:36002579 · one of two readings recorded this

• Dizziness

  no effect, p = 0.05

  dizziness (OR = 2.10, 95% CI 1.00–4.41, P = 0.05)

  PMID:36002579 · one of two readings recorded this

• Headache

  no effect, p = 0.99

  headache (OR = 1.01, 95% CI 0.43–2.36, P = 0.99)

  PMID:36002579 · one of two readings recorded this

• latency to onset of persistent sleep (LPS), polysomnography, minutes

  decreases, MD = − 19.30, 95% CI − 37.28 to − 1.32, p = 0.04

  Not recorded as a finding: sleep-onset-latency node exists but the paper prints only the abbreviation LPS, which is not among the node's accepted object spans; boundary not safely met

  Compared with the control group, trazodone significantly increased TST (MD = 39.88, 95% CI 14.44–65.32, P = 0.002) and N3 (SMD = 1.61, 95% CI 0.69–2.53, P = 0.0006); trazodone significantly decreased LPS (MD = − 19.30, 95% CI − 37.28 to − 1.32, P = 0.04), N1 (SMD = − 0.62, 95% CI − 1.13 to − 0.12, P = 0.02), NAs (SMD = − 0.67, 95% CI − 0.91 to − 0.42, P < 0.00001), and WASO (SMD = − 0.42, 95% CI − 0.81, − 0.03, P = 0.04).

  PMID:36002579 · one of two readings recorded this

• Latency to onset of persistent sleep (LPS)

  decreases, p = 0.04

  LPS | P < 0.00001; I2 = 97% | − 19.30 | − 37.28, − 1.32 | 2.10 | 0.04 | 0.085

  PMID:36002579 · one of two readings recorded this

• Latency to onset of persistent sleep (LPS)

  decreases, p = 0.00001

  LPS | 0 | − 39.36 | − 40.64, − 38.09 | 60.57 | < 0.00001 | < 0.00001

  PMID:36002579 · one of two readings recorded this

• Latency to onset of persistent sleep (LPS)

  decreases, p = 0.00001

  LPS | 4 | − 9.02 | − 12.88, − 5.16 | 4.58 | < 0.00001

  PMID:36002579 · one of two readings recorded this

• Latency to onset of persistent sleep (LPS)

  decreases, p = 0.0004

  LPS(I2 = 10%, MD = − 9.85, 95% CI − 15.34 to − 4.37, P = 0.0004)

  PMID:36002579 · one of two readings recorded this

• Latency to onset of persistent sleep (LPS)

  decreases, p = 0.005

  LPS | 28 | − 17.60 | − 29.83, − 5.36 | 2.82 | 0.005

  PMID:36002579 · one of two readings recorded this

• Latency to onset of persistent sleep (LPS)

  decreases, p = 0.0001

  LPS | 0 | − 8.47 | − 12.49, − 4.45 | 4.13 | < 0.0001 | 0.16

  PMID:36002579 · one of two readings recorded this

The whole record — 266 rows